Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 1/20 | 1.00 |
| ▸ | CASP3 | P42574 | 5/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | CASP9 | P55211 | 1/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.56 |
| ▸ | TGM2 | P21980 | 5/20 | 0.55 |
| ▸ | CES1 | P23141 | 3/20 | 0.55 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL5858452 | 0.81 | CA12 (0.69) | CA1CA2CA12CA9CASP3 | |
| SCHEMBL454611 | 0.81 | CA12 (0.69) | CA1CA2CA12CA9CASP3 | |
| SCHEMBL458636 | 0.81 | CA12 (0.69) | CA1CA2CA12CA9CASP3 | |
| SCHEMBL5893648 | 0.81 | CA12 (0.69) | CA1CA2CA12CA9CASP3 | |
| SCHEMBL30555218 | 0.81 | CA12 (0.69) | CA1CA2CA12CA9CASP3 | |
| SCHEMBL565240 | 0.81 | CA12 (0.69) | CA1CA2CA12CA9CASP3 | |
| SCHEMBL9473018 | 0.80 | CA1 (0.67) | CA1CA2CA12CA9PDPK1 | |
| SCHEMBL31388440 | 0.80 | PDPK1 (0.67) | CA1CA2CA12CA9PDPK1 | |
| SCHEMBL9473024 | 0.80 | CA1 (0.67) | CA1CA2CA12CA9PDPK1 | |
| Hydrochloric Acid SCHEMBL5184450 | 0.80 | CA12 (0.67) | CA1CA2CA12CA9CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108299280-A | Isatin -5- the sulfonamide inhibitors inhibited to mixed lineage leukemia key protein | 天津国际生物医药联合研究院 | 2018-07-20 | — | — | CN | claimed |
| EP-3456718-B1 | ISATIN-DERIVED COMPOUNDS, USE OF THE COMPOUNDS FOR THE TREATMENT OF AIDS AND HBV INFECTIONS | FUNDACAO OSWALDO CRUZ (BR) | 2021-02-17 | — | — | EP | disclosed |
| CN-108299280-A | Isatin -5- the sulfonamide inhibitors inhibited to mixed lineage leukemia key protein | 天津国际生物医药联合研究院 | 2018-07-20 | — | — | CN | disclosed |
| EP-2367816-B1 | ISATIN DERIVATIVES FOR USE AS IN VIVO IMAGING AGENTS | IMP INNOVATIONS LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| CN-103183631-B | Isatin-5-sulfonic acid amide derivatives and the application in the medicine of preparation treatment severe acute respiratory syndrome thereof | 天津市国际生物医药联合研究院 | 2016-08-24 | — | — | CN | disclosed |
| CN-103183631-B | Isatin-5-sulfonic acid amide derivatives and the application in the medicine of preparation treatment severe acute respiratory syndrome thereof | 天津市国际生物医药联合研究院 | 2016-08-24 | — | — | CN | disclosed |
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-8961930-B2 | Isatin derivatives for use as in vivo imaging agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6541503-B2 | Preventing chemotherapy induced alopecia. | SMITHKLINE BEECHAM CORPORATION | 2003-04-01 | — | — | US | disclosed |
| US-20030004351-A1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-01-02 | — | — | US | disclosed |
| EP-1231916-A2 | USE OF INDIRUBINE DERIVATIVES FOR MAKING MEDICINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-08-21 | — | — | EP | disclosed |
| US-6387919-B1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | GLAXO WELLCOME INC. | 2002-05-14 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| WO-2001037819-A2 | USE OF INDIRUBINE DERIVATIVES FOR MAKING MEDICINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2001-05-31 | — | — | WO | disclosed |
| EP-1009738-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999015500-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | CA1 2095/4885CA2 2772/4885CA12 2681/4885 |
| US-20030004351-A1 | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors | CDK2, CDK1, CCNI | CA1 2237/4885CA2 2406/4885CA12 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.